Osmind Raises $40M in Series B Funding

Osmind

Osmind, a San Francisco, CA-based public benefit corporation helping clinicians and researchers advance new life-saving mental health treatments, raised $40M in Series B funding.

The round, which brings the total amount of funding to $57m since founding in 2020, was led by DFJ Growth, with participation form Susa Ventures, Lachy Groom, Brent Saunders, Helena Goodman and Ariel Katz, General Catalyst, Future Ventures, Tiger Global, and Pear VC. Justin Kao, partner at DFJ Growth, and the co-founder of Helix, will join the Osmind Board of Directors.

The company intends to use the funds to continue to develop and scale its electronic health record (EHR) technology for mental health research and treatment, advance research with new partners, and double the size of the team virtually and at its San Francisco office.

Led by CEO Lucia Huang, and COO Jimmy Qian, Osmind is a public benefit corporation that helps the medical community administer, track, and study the efficacy of interventions such as ketamine, SPRAVATO®, and transcranial magnetic stimulation for the 14 million U.S. patients living with moderate and serious mental illness. 

The Osmind EHR platform is designed for the needs of mental health clinicians, including psychiatrists and other specialties, with tools such as streamlined charting workflows, secure patient engagement, and automated outcomes tracking. Clinicians are also part of the Osmind research program, which works with scientists to conduct clinical trials and analyze anonymized, aggregated real-world information to advance new diagnostics, therapeutics, and precision medicine approaches.

FinSMEs

10/05/2022